IP Library Granted Patent US 10,328,152
Granted Patent B2
US 10,328,152 · App. 15/240,871 · Granted Jun 25, 2019

Method for stabilization and delivery of therapeutic molecules

Inventors: Nayan Patel (La Habra, CA); Chinh Tran (La Habra, CA)
Assignee: Nayan Patel
A61K47/40A61K9/0014A61K9/1617A61K31/198A61K31/34A61K31/355A61K31/375A61K31/385A61K31/724A61K38/063A61K38/16A61K47/186A61K47/22A61K47/42
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,328,152
App. No.
15/240,871
Granted
Jun 25, 2019
Kind
B2
Abstract

A method of treatment is disclosed, comprising administering a composition of Cyclodextrin and reduced, nanonized L-Glutathione to a patient in need of treatment, wherein the L-Glutathione molecule is non-acetylated, non-Esterified, and non-fatty acid attached.

Claims (23)

1. A topical composition comprising:

an inclusion complex comprising: reduced glutathione, an additional antioxidant, and gamma cyclodextrin;

wherein the reduced glutathione is non-esterified, non-acetylated, and non-fatty acid attached,

wherein the additional antioxidant comprises at least one of the following: alpha-lipoic acid, ascorbic acid, uric acid, beta-carotene, alpha-tocopherol, dimethylethanolamine (DMAE), CoEnzyme Q10, vitamin E, carnosine, colloidal silver, catalase, superoxide dismutase, and peroxidase;

wherein the molar ratio of reduced glutathione to gamma cyclodextrin is between about 4:1 and 13:1;

wherein the complex is pH stabilized to a pH of between about 4.0 and about 7.8; and

wherein ultrasonic waves nanonize the pH stabilized complex into nanoparticles having a particle size range between 2 to 200 nanometers in order to facilitate rapid absorption into the bloodstream.

2. The composition of claim 1 , wherein the molar ratio of reduced glutathione to gamma cyclodextrin is between about 8:1 and 10:1.

3. The composition of claim 1 , wherein about 20% of the composition consists of reduced glutathione and about 10% of the composition consists of gamma cyclodextrin.

4. The composition of claim 1 , wherein about 55% of the composition consists of reduced glutathione and about 25% of the composition consists of gamma cyclodextrin.

5. The composition of claim 1 , wherein about 7% of the composition consists of reduced glutathione and about 3.35% of the composition consists of gamma cyclodextrin.

6. The composition of claim 1 , wherein the additional antioxidant comprises at least one of the following: ascorbic acid, DMAE, carnosine, lipoic acid, and superoxide dismutase.

7. The composition of claim 1 , wherein the additional antioxidant is ascorbic acid at a concentration of about 4% by mass.

8. A topical composition comprising:

an inclusion complex comprising: reduced glutathione, an additional antioxidant, and gamma cyclodextrin;

wherein the reduced glutathione is non-esterified, non-acetylated, and non-fatty acid attached;

wherein the reduced glutathione is stabilized in a reaction mixture by bringing the reduced glutathione and the additional antioxidant in contact with the gamma cyclodextrin solubilized in a polar solution, wherein the molar ratio of reduced glutathione to gamma cyclodextrin is between about 4:1 and 13:1;

wherein the additional antioxidant comprises at least one of the following: alpha-lipoic acid, ascorbic acid, uric acid, beta-carotene, alpha-tocopherol, dimethylethanolamine (DMAE), CoEnzyme Q10, vitamin E, carnosine, colloidal silver, catalase, superoxide dismutase, and peroxidase;

wherein the reaction mixture is capped under vacuum after mixing at a pH range of 3.0 to 7.0; and

wherein ultrasonic waves nanonize the pH stabilized complex into nanoparticles having a particle size range between 2 to 200 nanometers in order to facilitate rapid absorption into the bloodstream.

9. The composition of claim 8 , wherein the polar solution comprises ascorbic acid.

10. The composition of claim 8 , wherein the molar ratio of reduced glutathione to gamma cyclodextrin is between about 8:1 and 10:1.

11. The composition of claim 9 , wherein the polar solution further comprises benzalkonium chloride.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 3, 2019
From: TRAN, CHINH
To: PATEL, NAYAN
Reel/Frame 049075/0428 →
Continuity (4)
Continuation In Part 14275625 · May 12, 2014
Division 13526332 · Jun 18, 2012
Provisional Application 61497869 · Jun 16, 2011
Related Publication 20170095561A1 · Apr 6, 2017
Cited By (4)
US 12,350,307 US 12,419,932 US 12,427,180 US 12,533,329